- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT05337566
Reduserer tilleggsbruk av preoperativ azitromycin posthysterektomiinfeksjoner
Infeksjoner etter hysterektomi - en placebokontrollert studie som sammenligner profylaktisk bruk av azitromycin og cefuroksim med enkelt cefuroksim
During hysterectomy bacteria may enter into the peritoneal cavity through vaginal opening and contaminate the healing tissues. The risk for deep infection after hysterectomy is about 5%. By reducing post-hysterectomy infections, it is possible to reduce individual burden of disease in addition to the direct and indirect financial costs. This study primary aim is to assess if prophylactic preoperative use of azithromycin in addition to generally used cefuroxime decreases post-hysterectomy infections as compared to cefuroxime only prophylaxis during 30 days after hysterectomy. Secondary aim is to assess if there is change in post-hysterectomy superficial infections, urinary tract infections, or post-operative fever between the cohorts and to report possible side-effects of the used antibiotics. In addition, the study finds out a possible role of bacterial vaginosis and microbiome n post-hysterectomy infections.
Studieoversikt
Status
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
- Navn: Päivi K Rahkola-Soisalo, Adj prof,MD
- Telefonnummer: +358504270411
- E-post: paivi.rahkola-soisalo@hus.fi
Studer Kontakt Backup
- Navn: Ninja Savonius, MD
- Telefonnummer: +358503466986
- E-post: ninja.savonius@hus.fi
Studiesteder
-
-
-
Helsinki, Finland
- Rekruttering
- Helsinki University Central Hospital
-
Ta kontakt med:
- Ninja Savonius, MD
- Telefonnummer: +358503466986
- E-post: ninja.savonius@hus.fi
-
Ta kontakt med:
- Päivi K Rahkola-Soisalo, Adj prof,MD
- Telefonnummer: +358 50 4270411
- E-post: paivi.rahkola-soisalo@hus.fi
-
Underetterforsker:
- Liisu Saavalainen, PhD, MD
-
Underetterforsker:
- Päivi Härkki, Adj prof, MD
-
Underetterforsker:
- Tomi Mikkola, Prof, MD
-
Underetterforsker:
- Veli-Jukka Anttila, Adj prof,MD
-
Underetterforsker:
- Seppo Virtanen, DI, MD
-
Underetterforsker:
- Anne Saloranta, Adj Prof
-
Underetterforsker:
- Ilkka Kalliala, Adj Prof, MD
-
Underetterforsker:
- Suvi Niku, PhD, MD
-
Jyväskylä, Finland, 40620
- Rekruttering
- Jyväskylä Central Hospital
-
Ta kontakt med:
- Jaana Seikkula, PhD
- Telefonnummer: +358 41 548 3562
- E-post: jaana.seikkula@fimnet.fi
-
Kuopio, Finland, 70029
- Rekruttering
- Kuopio University Central Hospital
-
Ta kontakt med:
- Henna Kärkkäinen, PhD
- Telefonnummer: +358 44 7172741
- E-post: henna.karkkainen@kuh.fi
-
Oulu, Finland, PL23
- Rekruttering
- Oulu University Central Hospital
-
Ta kontakt med:
- Sari Koivurova, PhD
- Telefonnummer: +358 8 3150211
- E-post: sari.koivurova@ppshp.fi
-
Tampere, Finland, 33521
- Rekruttering
- Tampere University Central Hospital
-
Ta kontakt med:
- Riikka Niemi, PhD
- Telefonnummer: +358 3 31169083
- E-post: riikka.niemi@pshp.fi
-
Underetterforsker:
- Elina Ylilehto, PhD, MD
-
Turku, Finland
- Rekruttering
- Turku University Central Hospital
-
Ta kontakt med:
- Pia Heinonen, PhD
- Telefonnummer: +358 2 313 5002
- E-post: pia.heinonen@tyks.fi
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Women undergoing hysterectomy for benign indication in University Hospitals (Helsinki University Hospital, Turku University Hospital, Tampere University Hospital, Oulu University Hospital and Kuopio University Hospital) who have not any contraindications for azithromycin or cefuroxime.
Exclusion Criteria:
- Inability to understand the study protocol.
- Allergy for either cefuroxime or azithromycin.
- Congenital or acquired prolonged Q-T-corrected interval. All the participants will be asked about arrhythmias and whether they have congenital arrhythmias in the family,
- Electrocardiogram will be checked for all the participants.
- Use of medicines that may prolong Q-T-corrected interval (class Ia arrhythmia medications, quinidine, procainamide, and class III arrhythmia medications dofetilide, amiodarone and sotalol).
- Use of selective serotonin reuptake inhibitor medication and prolonged Q-T-corrected interval.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Forebygging
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Trippel
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Azithromycin + Cefuroxime
Changed with renewed study permissions: These patients will receive Azithromycin 500 mg (2 tablets) per orally on the operation day when they arrive to the hospital and a single dose Cefuroxime 1.5g (when body mass index is under 30) or 3g (for those whose bosy mass index is 30 or more) in the operating theatre before the incision. The previous description: These patients will receive Azithromycin 500 mg (2 tablets) per orally in the evening before the operation and single dose Cefuroxime 1.5g (when body mass index is under 30) or 3g (for those whose body mass index is 30 or more) in the operating theatre before the incision. |
Azithromycin 500 mg (2 tablets) per orally when arriving to the hospital before the operation and a single dose Cefuroxime 1.5g (when body mass index is under 30) or 3g (for those whose body mass index is 30 or more) in the operating theatre before the incision |
|
Aktiv komparator: Placebo + Cefuroxime
Changed with new study permissions: These patients will receive placebo (2 tablets) per orally on the operation day when they arrive to the hospital and a single dose Cefuroxime 1.5g (when body mass index is under 30) or 3g (for those whose bosy mass index is 30 or more)in the operating theatre before the incision. The previous description: These patients will receive placebo (2 tablets) per orally in the evening before the operation and a single dose Cefuroxime 1.5g (when body mass index is under 30) or 3g (for those whose body mass index is 30 or more) in the operating theatre before the incision. |
Placebo (2 tablets) per orally in the evening when arriving to the hospital before the operation and a single dose Cefuroxime 1.5g (when body mass index is under 30) or 3g (for those whose body mass index is 30 or more) in the operating theatre before the incision |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of post-hysterectomy episodes with deep infections
Tidsramme: Deep infections that occur between the first and 30th postoperative day after hysterectomy
|
Number of deep wound and pelvic organ infection episodes reported by patients and doctors |
Deep infections that occur between the first and 30th postoperative day after hysterectomy
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of other post-hysterectomy infections or fever episodes
Tidsramme: Number of other infections or fever episodes that occur between the first and 30th postoperative day after hysterectomy.
|
Number of superficial infections, other infections, such has urine tract infections, or fever episodes lasting over 38 ℃ over 2 days |
Number of other infections or fever episodes that occur between the first and 30th postoperative day after hysterectomy.
|
Samarbeidspartnere og etterforskere
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Päivi Rahkola-Soisalo, Adj prof, MD, Helsinki University Central Hospital
- Studiestol: Tomi Mikkola, Prof, MD, Helsinki University Central Hospital
- Studieleder: Päivi Rahkola-Soisalo, Adj prof, MD, Helsinki University Central Hospital
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- HUS/117/2022
- 2021-003467-10 (EudraCT-nummer)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .